Sanofi’s Wayrilz approved in the EU as the first BTK inhibitor to treat immune thrombocytopenia Novel treatment targets BTK through multi-immune modulation to help address the underlying causes of ITPApproval based on the LUNA 3 phase 3 study that demonstrated rapid and durable platelet response and improvements in other ITP symptomsITP is a rare disease of complex immune dysregulation leading to lower platelet counts, bleeding, and reduced quality of life Paris, December 23, 2025 – The European Commission ...

PLEASED TO SAY IS THE CEO OF NOVO NORDISK, MIKE DOUSTDAR. GREAT TO HAVE YOU WITH US. JUST TO SET THE SCENE WHEN IT COMES TO THE U.S. MARKET, YOU HAVE BEEN LOSING SHERRY TO ELI LILLY FOR A COUPLE YEARS NOW. WITH THIS APPROVAL, YOU HAVE AN IMPORTANT FIRST MOVER ADVANTAGE WHEN IT COMES TO ORAL GLP-1'S.GIVEN THAT YOU EXPECT TO SELL THE PILL VERSION OF WEGOVY IN JANUARY AND ELI LILLY IS NOT DUE UNTIL MARCH, HOW DO YOU PLAN TO MAKE THE MOST OF THIS HEAD START. MIKE: THANK YOU FOR HAVING ME. AS THEY SAY, CHRISTMAS ...

Core Viewpoint - Artelo Biosciences, Inc. sees the White House's Executive Order on a Medicare pilot program for cannabidiol (CBD) products as a significant milestone for recognizing CBD's therapeutic potential and improving access to cannabinoid-based treatments for vulnerable populations [2][3] Company Positioning - Artelo is positioned to address the need for standardized, effective CBD therapies through its proprietary product ART12.11, which has shown superior oral bioavailability and consistent pharmacokinetics compared to standard CBD formulations [4][5] - The company emphasizes the importance of rigorous clinical studies to establish the safety and efficacy of CBD-based treatments, distinguishing them from consumer-grade products [3][6] Product Development - ART12.11 is a patented cocrystal composition of CBD and tetramethylpyrazine (TMP), designed to ensure pharmaceutical-grade purity and potency, essential for clinical development and potential reimbursement [5][7] - Following positive feedback from regulatory authorities, Artelo is ready to advance ART12.11 into human clinical trials, aligning with the goals of the Executive Order to provide data-driven confidence in medical CBD use [6][7] Market Opportunity - The Executive Order's focus on data collection for CBD products indicates a growing demand for safe and effective cannabinoid therapies, particularly for aging and medically vulnerable populations [2][3] - Artelo's ART12.11 is expected to meet the standards required for federal healthcare integration and prescription-based use, representing a next-generation approach to cannabinoid medicine [7]

NEW YORK, Dec. 23, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Telix Pharmaceuticals Ltd. ("Telix Pharmaceuticals Ltd." or the "Company") (NASDAQ: TLX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Telix Pharmaceuticals Ltd. investors who were adversely affected by alleged securities fraud between February 21, 2025 and August 28, 2025. Follow the link below to get more information and be contacted by a member of our team: https ...

Core Insights - Scilex Holding Company announced the confirmed claim process for the Dream Bowl 2026 Meme Coins, set to begin on December 24, 2025, for eligible shareholders [1][2]. Company Overview - Scilex is focused on acquiring, developing, and commercializing non-opioid pain management products aimed at treating acute and chronic pain, as well as neurodegenerative and cardiometabolic diseases [4][6]. - The company targets high unmet needs in the market with its non-opioid therapies, aiming to improve patient outcomes [4]. Commercial Products - Scilex's commercial products include: - ZTlido® (lidocaine topical system) 1.8%, approved by the FDA for neuropathic pain relief [4]. - ELYXYB®, the only FDA-approved ready-to-use oral solution for acute migraine treatment in adults [4]. - Gloperba®, the first liquid oral version of colchicine for the prophylaxis of painful gout flares in adults [4]. Product Candidates - Scilex has three product candidates in development: - SP-102 (SEMDEXA), a viscous gel formulation for treating lumbosacral radicular pain, which has completed a Phase 3 study and received Fast Track status from the FDA [5]. - SP-103, a next-generation lidocaine topical system for acute pain, which has recently completed a Phase 2 trial and also received Fast Track status from the FDA [5]. - SP-104, a low-dose delayed-release naltrexone hydrochloride for fibromyalgia treatment [5].

As investors look beyond mega-cap tech for the next leg of growth, pharma is quietly moving back into focus — and no two names capture that shift better than Eli Lilly And Co (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO) .Track LLY stock here.GLP-1 Demand Is Becoming StructuralThe obesity and diabetes drug boom is no longer a one-cycle story. Demand for GLP-1 treatments continues to exceed supply, with physicians expanding use beyond diabetes into weight management and cardiovascular risk reduction.That long-t ...

Core Insights - Amplia Therapeutics Limited is set to present updated data from the ACCENT trial at the ASCO Gastrointestinal Cancers Symposium, focusing on the combination of Narmafotinib with gemcitabine and nab-paclitaxel for metastatic pancreatic cancer [1][2] Company Overview - Amplia Therapeutics Limited is an Australian pharmaceutical company specializing in Focal Adhesion Kinase (FAK) inhibitors aimed at treating cancer and fibrosis, with a focus on fibrotic cancers such as pancreatic and ovarian cancer [2] - FAK is recognized as a significant target in cancer treatment and is also involved in chronic diseases like idiopathic pulmonary fibrosis (IPF) [2] Drug Information - Narmafotinib (AMP945) is a potent and selective FAK inhibitor, currently in clinical trials, showing promising results in preclinical studies [3] - The ACCENT trial has achieved a confirmed response rate of 35%, surpassing the 23% response rate from the benchmark MPACT study for gemcitabine and Abraxane alone, with an interim median progression-free survival (PFS) of 7.6 months [3] - A second trial, AMPLICITY, is underway, investigating the combination of Narmafotinib with FOLFIRINOX in advanced pancreatic cancer patients [3]

I am focused on growth and dividend income. My personal strategy revolves around setting myself up for an easy retirement by creating a portfolio which focuses on compounding dividend income and growth. Dividends are an intricate part of my strategy as I have structured my portfolio to have monthly dividend income which grows through dividend reinvestment and yearly increases. Feel free to reach out to me on Seeking AlphaAnalyst’s Disclosure:I/we have a beneficial long position in the shares of BMY, PFE eit ...

Market Overview - The Russell 2000 index experienced a rally of more than 1% recently, indicating positive market sentiment [1] - The market is currently in a pause mode, awaiting the release of significant economic data throughout the day [2] - Small-cap stocks are outperforming, suggesting a potential shift in market dynamics [3] Economic Indicators - Key economic data points to watch include GDP, durable goods orders, and consumer confidence, with consumer confidence expected to have a notable impact on consumer discretionary and staples stocks [6][7][8] - The GDP data is anticipated to show a potential downward adjustment, influenced by data center spending, which constitutes around 70% of GDP [6][7] Metals Market - Gold has reached its 50th record high this year, while silver is also experiencing significant upward movement, with speculation about crossing the $70 per ounce mark [9][10] - Strong buying interest in silver futures indicates a foundation for continued price increases, while gold is expected to potentially reach $4700 [10][11] - The metals market is influenced by various factors, including monetary policy and currency devaluation, which serve as tailwinds for precious metals [12] Copper Market - Copper is facing a structural deficit, with mining companies revising production levels downward for 2026, contributing to price support [14][15] - The anticipated global AI build-out may also provide a rebound trade for copper, further supporting its price [16] Novo Nordisk - Novo Nordisk shares rose approximately 8% in premarket trading following FDA approval of the Wegovy pill, which could revolutionize the weight loss drug market [18][19] - Despite this positive news, Novo's stock is still down about 74% year-to-date, indicating potential for a rotation trade as investors seek value in the pharmaceutical sector [20][21] - In contrast, Eli Lilly's shares have increased nearly 40% year-to-date but are under pressure due to the competitive landscape following Novo's announcement [22]

Core Insights - Dividend Kings are companies that have increased their dividend payments for at least 50 consecutive years, providing a reliable long-term investment strategy [1] - Several Dividend Kings, including Coca-Cola, Johnson & Johnson, and Consolidated Edison, have achieved over 100% total return in the past decade, suggesting a potential for doubling investments in the next 10 years through a buy-and-hold strategy [1] Group 1: Coca-Cola - Coca-Cola increased its dividend payment by 5.2% this year, marking its 63rd consecutive year of dividend growth [3] - The company has delivered a total return of approximately 125% over the past decade, equating to an annualized return of 8.4% [3][4] - Coca-Cola aims for organic revenue growth of 4% to 6% per year and high-single-digit earnings-per-share growth, supported by a strong balance sheet and significant investments in product innovation and marketing [4][5] Group 2: Johnson & Johnson - Johnson & Johnson raised its dividend payment by 4.8% this year, also extending its dividend growth streak to 63 years [6] - The company has achieved a total return exceeding 165% over the past decade, with an annualized return of 10.3% [6] - Johnson & Johnson holds a AAA bond rating, indicating a strong financial profile, and consistently produces resilient earnings [8]